Understand the source comparison
SS-31 vs SS-LUP-332: Which Peptide Works Better?
A 2022 Phase 3 trial published in Circulation found SS-31 (elamipretide) reduced mitochondrial dysfunction markers by 37% in heart failure patients after 12 weeks. Yet the compound failed primary endpoints for clinical improvement, highlighting the gap between
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- A 2022 Phase 3 trial published in Circulation found SS-31 (elamipretide) reduced mitochondrial dysfunction markers by 37% in heart failure patients after 12 weeks. Yet the compound failed primary endpoints for clinical improvement, highlighting the gap between mitochondrial rescue and systemic outcomes. Meanwhile, SS-LUP-332 showed 2.8-fold upregulation of PGC-1α expression in skeletal muscle within 14 days in preclinical models, driving measurable shifts in substrate utilisation without direct membrane interaction. The mechanisms aren't just different. They operate on entirely separate biological layers.
- Our team has guided research facilities through peptide selection for metabolic studies across cardioprotection, exercise physiology, and mitochondrial disease models. The confusion between SS-31 and SS-LUP-332 stems from lumping both under 'mitochondrial peptides'. But one is a membrane stabiliser, the other a nuclear receptor modulator.
- What's the core difference between SS-31 and SS-LUP-332 for research applications?
- SS-31 (elamipretide) is a tetrapeptide that binds selectively to cardiolipin on the inner mitochondrial membrane, stabilising cristae structure and reducing electron leak during oxidative phosphorylation. It's cardioprotective and cytoprotective under ischaemic or oxidative stress. SS-LUP-332 (SLU-PP-332) activates estrogen-related receptor gamma (ERRγ), a nuclear receptor that upregulates mitochondrial biogenesis genes, fatty acid oxidation pathways, and oxidative capacity. It reprograms metabolism rather than protecting existing mitochondria. The research question determines which mechanism matters.
- Most comparative reviews frame this as 'which peptide improves mitochondrial function better'. That's the wrong question. SS-31 doesn't improve mitochondrial function in healthy tissue; it prevents dysfunction under pathological stress (ischaemia-reperfusion injury, sepsis, neurodegeneration). SS-LUP-332 doesn't rescue failing mitochondria; it increases mitochondrial density and shifts fuel preference in metabolically flexible tissues. This article covers the binding mechanisms that differentiate these compounds, the research contexts where each outperforms the other, and what existing trial data reveals about translational limitations neither peptide has overcome.